Considering the beneficial effects of the CDR-induced HTRA2 protease inhibition on RGCs ex vivo [16], this might also indicate a pathogenic role of these processes in the pathogenesis of glaucoma; i.a. by hyperactivation. This evidence concerns the gene HTRA2 and glaucoma.